Related Experiment Video
Updated: May 5, 2026

Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition
Published on: September 3, 2016
Inhibitory potential of pentagalloyl glucose against efflux pumps in Staphylococcus aureus
Kiran Harikumar1,2, Udisha Singh1, Subakamakshi Krishnaswamy Ramaraj1
1Bioinformatics Laboratory, BRIC-Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014 India shijulalns@rgcb.res.in.
Abstract:
Antibiotic resistance in Gram-positive priority pathogens is mediated by a diverse set of mechanisms such as target protection, antibiotic inactivation, decreased uptake, antibiotic efflux, etc. In Staphylococcus aureus, efflux pumps of the major facilitator superfamily (MFS) expel various antibiotics and multiple efflux pumps are activated upon antibiotic exposure. Efflux pump inhibitors (EPIs) that can act as antibiotic adjuvants are proposed to be promising solutions to tackle antibiotic resistance. In this study, in silico screening of 17 967 phytochemical compounds from Indian medicinal plants (IMPPAT 2.0) against four key MFS efflux pumps activated by fluoroquinolone exposure (NorA, NorB, NorC, and SdrM) followed by in vitro validation identified a tannin derivative, pentagalloyl glucose (PGG), as a potential efflux pump inhibitor (EPI) with high binding affinity. Molecular docking scores (≤-16.383 kcal mol-1) and MM/GBSA binding affinities (≤-100.62 kcal mol-1) indicate a strong interaction between PGG and its targeted efflux pumps. PGG forms stable interactions via hydrogen bonding with key residues of NorA, including GLU222 and ASP307, which are crucial for proton-coupled transport. Likewise, it interacts with essential residues in NorB (SER147, ASN280), NorC (ASN276, LYS398), and SdrM (SER143, GLN283), forming strong hydrogen bonds that contribute to its inhibitory potential. The stability of PGG-bound complexes was confirmed through molecular dynamics simulations over 100 ns in triplicates, along with free energy landscape (FEL) and principal component analysis (PCA). Furthermore, PGG's synergistic action with ciprofloxacin, and effects on S. aureus growth dynamics were validated using the checkerboard assay, and time-kill kinetic studies, respectively. Following further structural optimization and in vivo studies, PGG can be considered a promising therapeutic candidate against multidrug-resistant S. aureus strains.
More Related Videos
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Probiotics
Inhibitors of Gram-positive Cell Wall Synthesis

